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Catalytic Nanoceria Are Preferentially Retained in the Rat
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Abstract
Cerium oxide nanoparticles (nanoceria) possess catalytic and regenerative radical scavenging activities. The ability of
nanoceria to maintain cellular redox balance makes them ideal candidates for treatment of retinal diseases whose
development is tightly associated with oxidative damage. We have demonstrated that our stable water-dispersed nanoceria
delay photoreceptor cell degeneration in rodent models and prevent pathological retinal neovascularization in vldlr mutant
mice. The objectives of the current study were to determine the temporal and spatial distributions of nanoceria after a
single intravitreal injection, and to determine if nanoceria had any toxic effects in healthy rat retinas. Using inductivelycoupled plasma mass spectrometry (ICP-MS), we discovered that nanoceria were rapidly taken up by the retina and were
preferentially retained in this tissue even after 120 days. We also did not observe any acute or long-term negative effects of
nanoceria on retinal function or cytoarchitecture even after this long-term exposure. Because nanoceria are effective at low
dosages, nontoxic and are retained in the retina for extended periods, we conclude that nanoceria are promising
ophthalmic therapeutics for treating retinal diseases known to involve oxidative stress in their pathogeneses.
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3+ and 4+ valence states and therefore can act as electron donors
or acceptors. Oxygen defects or vacancies on the surface or
subsurface of the lattice crystals act as sites for radical scavenging
[5,6]. When synthesized in the 3–5 nm range, nanoceria possess
enhanced catalytic activities that mimic superoxide dismutase and
catalase [7–9], two major anti-oxidative enzymes, to neutralize
superoxide anions and hydrogen peroxides, respectively. The
enhanced redox capacity of nanoceria is most likely due to the
dramatically increased surface to volume ratio of these nanoparticles.
Accumulating evidence has shown that the disease progression
of many neurodegenerative conditions such as Alzheimer’s,
Parkinson’s and retinal degenerative diseases including age-related
macular degeneration, diabetic retinopathy, and various forms of
retinitis pigmentosa, are tightly associated with oxidative damage
due to either chronically or acutely increased reactive oxygen
species [10–16]. During the past few years, we have focused on

Introduction
Nanomaterials which include nano-sized and nano-structured
objects, have gained importance in biomedical research and
medicine in recent years. Because of the dramatic increase in
surface area when synthesized in the nanometer range, nanomaterials exhibit enhanced or unique reactivity that is not found in
their macroscopic counterparts. Many promising nanomaterials
are currently under investigation for drug or nucleic acid delivery
to target specific organ/tissue for therapy. Others are tested for
diagnostic, imaging, tissue healing, and surgical aids [1]. Another
unique class of nanomaterials, namely the redox-active radical
scavenging nanoparticles including fullerenes and cerium oxide
nanoparticles (nanoceria or CeNPs), is being developed as bona
fide antioxidants for treatment of neurodegenerative diseases [2–
4].
The oxides of cerium, a rare earth element, have unique
physical and chemical properties. The cerium ions have both the
PLOS ONE | www.plosone.org
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thoroughly characterized using transmission electron microscopy
(size and shape determination), dynamic light scattering (zeta
potential measurement), and X-ray photoelectron spectroscopy
(estimating the oxidation state of cerium) as described in [18].
Each batch was validated for the abundance of catalytically active
Ce3+ oxidation state and stable aqueous dispersion. More
importantly, we did not use hexamethylenetetramine (HMT) in
the synthesis of nanoceria due to cytotoxic effects exhibited by
nanoparticles prepared in this manner (unpublished observation).

developing our stable water-dispersed nanoceria as ophthalmic
therapeutics for treatment of retinal diseases. We showed that
these nanoceria increased the lifespan of retinal neurons in culture
and protected them from oxidative damage when challenged with
hydrogen peroxide [17]. Nanoceria synthesized using the same
methodology also protected photoreceptor cells in a light-induced
retinal degeneration model [17]. They inhibited the development
and caused the regression of pathologic retinal neovascularization
in the very low density lipoprotein receptor (vldlr) knockout mouse [18].
These nanoceria also delayed the degeneration of photoreceptor
cells in a retinal degeneration mouse carrying the tubby mutation
[19].
Despite the well-documented ability of nanoceria to reduce
oxidative damage, retinal degeneration, and inflammation [17–
20], the mechanisms of radical scavenging by nanoceria in
biological systems are still unclear [2,21]. Furthermore, the biodistribution and pharmacokinetics of nanoceria in ocular tissues
after a single intravitreal injection (the optimal route for nanoceria
delivery) are unknown. Nanoceria appear to have differential
effects in different cell types. From cell culture studies, certain cell
types exhibited enhanced longevity and protection from oxidative
insults while a few showed reduced viability when exposed to
nanoceria at specific dosages [2,22]. Currently, a systematic study
of nanoceria cytotoxicity in vivo in ocular tissues is lacking. We
therefore carried out a detailed study to specifically address these
fundamental questions to characterize the interactions of nanoceria in the unique biological environment of the eye. We used
inductively-coupled plasma mass spectrometry (ICP-MS), a highly
sensitive method for trace element detection in biological samples,
to study the bio-distribution of nanoceria after a single intravitreal
injection in the rat eye. We discovered that nanoceria were rapidly
and preferentially retained in the retina for at least 120 days. We
also showed that nanoceria were not toxic to retinal cells over a
range of dosages applied. Our study is the first to demonstrate that
nanoceria are retained in the retina for an extended period after a
single intravitreal injection and that nanoceria do not have toxic
side effects in retinal cells in vivo at the dosage levels applied.

4. Intravitreal Injection of Nanoceria
Adult SD rats (8 weeks or older) were selected for intravitreal
injection. Animals were anesthetized by intramuscular injection of
a mixture of ketamine (80 mg/kg) and xylazine (4 mg/kg). Pupils
were dilated by application of a drop of phenylephrine (10%
solution) to the cornea before the delivery of 2 ml of either CeNPs
of varying dosages (1 mM or 0.344 ng to 1 mM or 344 ng in saline
solution) or saline alone into the vitreous with the aid of an
ophthalmic operating microscope. Both eyes of each animal
received the same treatment.

5. Sample Collection for Inductively Coupled Plasma
Mass Spectrometry (ICP-MS)

Materials and Methods

Eyes were harvested at designated times post injection. Enucleated eyes were fixed in 4% (para-formaldehyde) PFA (in 0.1M
phosphate buffer, pH 7.4) at 4uC until ICP-MS analysis. If further
dissection was performed, eyes were fixed at room temperature for
30 minutes before dissection. Eyes were dissected into component
parts in cold PBS, pH 7.4. Ocular components: retina (R), lens (L),
rest of eyecup including cornea, iris, retinal pigment epithelium,
choroid, and sclera (EC) or whole eyes were kept in individual
Eppendorf tubes containing 1 ml 4% PFA and stored at 4uC until
processing for ICP-MS. In most cases (80%), the vitreous body was
found associated with the lens tissue and was included in the lens
component. When the vitreous body was not associated with the lens
tissue, it was discarded in the dissecting buffer. We confirmed that
inclusion of the vitreous body in the lens component did not alter the
amount of nanoceria in the lens component.

1. Animal

6. ICP-MS

We kept a breeding colony of Sprague-Dawley (SD) albino rats
in the Dean McGee Eye Institute (DMEI) vivarium under cyclic
light conditions (12 h on/12 h off, 5–20 lux).

Tissues in 1 ml fixative were mixed in 10 ml 70% nitric acid
overnight to start the digestion process. Samples were then
microwave-digested in an Xpress Microwave Digester. The
temperature was ramped to 200uC over a span of 20 minutes and
held there for another 20 minutes. Samples were then boiled down to
less than 1 ml each and reconstituted in water to 10 ml exactly. The
Ce levels were assessed using a 7700 Series ICP-MS from Agilent
Technologies (Santa Clara, CA). The level of Ce was converted to
CeO2 for data presentation. Each time point represented the
average from at least four eyes from two individual rats.

2. Ethics Statement
Animals were cared for and handled according to the
Association for Research in Vision and Ophthalmology statement
for the use of animals in vision and ophthalmic research. The
study was approved by the University of Oklahoma Health
Sciences Center Institutional Animal Care and Use Committee
(OUHSC IACUC) and the DMEI IACUC. The approved
protocol numbers were 10-087 and 10-088 from the OUHSC
IACUC, and D-10-087 and D-10-088 from the DMEI IACUC.

7. Electroretinogram Recordings (ERG)
Animals were dark adapted overnight and manipulated under
dim red light. Anesthesia was induced with a mixture of ketamine
(80 mg/kg i.m.) and xylazine (4 mg/kg i.m.) and the animal was
placed on a thermal water heated pad with the temperature
controlled (38uC) by a circulating water pump (GAYMAR T/
PUMP, Orchard Park, NY). Pupils were dilated at least five
minutes before testing using a topical phenylephrine (10%)
solution (AK-DILATE, Akorn, Inc., Lake Forest, IL). A drop of
2.5% hypromellose solution (GPS, Wilson Ophthalmic, Mustang,
OK) was applied to the cornea to prevent dehydration and allow
for electrical contact with the gold recording electrode (Goldring

3. Synthesis of Nanoceria
Cerium oxide nanoparticles were synthesized using simple wet
chemistry methods as described previously [23]. Briefly, stoichiometric amounts of cerium nitrate hexahydrate (99.999% from
Sigma Aldrich) were dissolved in deionized water. The solution
was oxidized using an excess amount of hydrogen peroxide. After
the synthesis of nanoparticles, the pH of the suspension was
maintained below 3.0 using nitric acid (1M) to keep the
synthesized nanoceria in suspension. These 3–5 nm particles were
PLOS ONE | www.plosone.org
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Electrode, 4 mm, Roland Consult, Stasche & Finger GmbH,
Brandenburg, Germany). A platinum subdermal needle (Grass
Technologies, West Warwick, RI) hooked into the mouth, right
side of the cheek, served as the reference electrode. To complete
the circuit, a platinum subdermal needle electrode was placed
under the skin at the base of the tail. The Espion system from
Diagnosys LLC (Lowell, MA) provided amplification (at 0.30 to
300 Hz bandpass, with notch filtering), stimulus presentation, and
data acquisition.
Scotopic. The scotopic stimuli consisted of white flashes
provided by a xenon bulb projected on a ganzfeld. The intensity of
stimuli evaluated and specifics of the protocol are shown in
Table 1. The amplitude of each A-wave response corresponded to
the maximum negative deflection found between 6 and 35 ms
after the stimulus. The amplitude of each B-wave response
corresponded to the difference between the maximum negative
deflection determined and the maximum positive deflection found
between 30 and 130 ms after the stimulus.
Photopic. The source of photopic stimuli was the same as the
one presented for scotopic stimuli and flashes were presented
consecutively at 0.06, 0.6, 3.0, 30.0, 300.0 and 600.0 cd.s/m2.
Prior to the first flash, a five minute light adaptation sequence was
used at a luminance of 30 cd/m2. A total of 10 responses were
averaged for each intensity tested with an inter trial delay of 1 s.
We determined the amplitudes of each A-, and B-wave response as
described under the Scotopic condition. Only B-wave amplitudes
are presented.
Flicker. The flicker stimuli at 30 cd.s/m2 flash intensity with
a background luminance of 30 cd/m2 were presented at 3 Hz,
5 Hz and then at 10–40 Hz in 10 Hz steps. For each flicker
frequency tested, the stimulus was presented followed by a 5 s
delay prior to data collection. This guaranteed that the first few
responses (not preceded by repeated stimuli and of potentially
greater amplitude) were excluded. The wave trains were examined
to ensure consistency of responses over the duration of stimuli
(500 ms). Amplitude from the first wave form from each frequency
was determined. Finally, presentation of the 3 Hz stimulus was
repeated to ascertain the stability of the responsiveness, i.e.
confirming that amplitudes obtained with this last trial were
comparable to those obtained with the first trial. The amplitude of
each flicker response corresponded to the difference between the
first maximum negative and the first positive deflections. These
protocols were modified from the ones described in [24,25].
Measurements from these ERG recordings enable us to evaluate
the functions of several classes of retinal neurons. Scotopic a-wave

amplitude reflects primarily the function of rod cells. Scotopic bwave amplitude reflects the function of neurons in the inner retina,
post-synaptic to the rod photoreceptor cells. Photopic b-wave
amplitude and flicker ERG reflect the function of cone cells [26].
Each data point represented the average from at least three
individual rats or six eyes.

8. Histology and Morphometric Analysis
After ERG recordings, the rats were euthanized with carbon
dioxide, the eyes enucleated and fixed in Prefer fixative (Anatech
Ltd., Battle Creek, MI) for 45 min. Five mm thick paraffin sections
were obtained along the superior/inferior axis of the globe
through the central retina. Hematoxylin and Eosin (H&E) stained
sections were used for morphometric analyses. Detailed description of each measurement is provided in Figure 1. Each data point
was from 2–5 eyes from different rats; all but 2 data points had
samples of at least 3 eyes.

9. Statistical Analysis
For ICP-MS data, each data point was averaged from 4–8 eyes
whereas ERG data were averaged from 6–10 eyes. Values were
expressed as means 6 SEM. Statistical analyses were performed
using one-way ANOVA followed by the Tukey multiple comparison tests comparing every group with every other group using
GraphPad Prism version 5.00 for Windows (GraphPad Software,
San Diego CA USA, www.graphpad.com). A P value less than
0.05 was considered significant and is indicated by an asterisk.

Results
1. Characterization of Nanoceria
Each batch of synthesized nanoceria was thoroughly characterized using (1.) transmission electron microscopy for size and
shape determination, (2.) dynamic light scattering for zeta
potential measurement, and (3.) X-ray photoelectron spectroscopy
for determination of the relative abundance of 3+ and 4+
oxidation state of cerium. The detailed characterization results
can be found in the supplemental materials in [18]. Our stable
water-dispersed nanoceria are 3–5 nm in size. The size of these
particles remains the same in a wide range of pH buffers and upon
aging [27]. The surface charge on nanoceria is an important
consideration for their interactions with the biological environment. We established that the zeta potential of our synthesized
nanoceria at 1 mM in saline solution to be +1063 mV [18].

Table 1. Parameters of the nine steps used for Scotopic ERG recording.

Step

Light intensity (cd.s/m2)

Light intensity Log
scale (cd.s/m2)

# trials per result

Inter trial delay (s)

1

0.006

22.22184875

4

10

2

0.009

22.045757491

4

10

3

0.03

21.522878745

3

15

4

0.06

21.22184875

3

15

5

0.3

20.522878745

3

20

6

3

0.477121255

3

25

7

30

1.477121255

3

30

8

300

2.477121255

2

50

9

600

2.77815125

2

60

doi:10.1371/journal.pone.0058431.t001
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Figure 2. Nanoceria were retained in the eye for months. The
amount of nanoceria retained in the eye was determined by ICP-MS.
The elimination was extremely slow with approximately 90% of the
injected nanoceria still retained in the eye at 120 days or four months
post injection.
doi:10.1371/journal.pone.0058431.g002

Figure 1. Parameters for evaluation of effects of nanoceria on
retinal cytoarchitecture. A. Schematic diagram of a cross section of
a rodent eye cut through the optic nerve head. The thick black line in
the posterior part of the globe represents the retina. Measurements
were taken from i) the central portion of the retina: 960 mm from the
optic nerve head (ONH), and ii) the peripheral portion of the retina:
960 mm from the ora serrata, along the superior and inferior axis of the
globe. Each marked interval represents ,960 mm. B. Photomicrograph
of an H&E stained retinal section to illustrate the measurements taken
from different retinal layers for quantitative analyses. Inner retina is up.
1 = retina thickness (RT) = inner limiting membrane (ILM) to outer
limiting membrane (OLM), 2 = inner nuclear layer (INL), 3 = outer nuclear
layer (ONL), 4 = inner and outer segments (IOS) of rod cells. To minimize
the effects of uneven tissue shrinkage among eye samples, we
normalized the thickness of INL, ONL, and IOS by comparing these
measurements with the overall thickness of the retina (RT). Measurements from a single retinal section were taken using a calibrated reticle
on one of the binoculars of a Nikon E400 microscope under a 20X
objective. Averages were from eyes of different animals.
doi:10.1371/journal.pone.0058431.g001

3. Nanoceria were Rapidly and Preferentially Taken up by
Retinal Cells
To determine where nanoceria were distributed after injection,
we dissected the eye into component parts. We separated the
retina and the lens from the rest of the eyecup before ICP-MS
analysis. Figure 3 shows the bio-distribution of nanoceria one
hour post injection. During this initial hour, retinal tissue
accumulated the highest concentration of nanoceria (17.89 ng/
mg tissue, followed by the lens tissue (1.13 ng/mg tissue), and the
lowest in the eyecup tissue (0.83 ng/mg tissue). Uninjected eyes
contained negligible amount of nanoceria.
To determine if nanoceria were also preferentially retained in
retinal tissue, we analyzed retinal samples from 1 hour to 120 days
post injection. Figure 4 shows the amount of nanoceria

2. Ninety Percent Of Injected Nanoceria Stayed in the Eye
for 120 Days
Since we did not know how quickly nanoceria were cleared in
the eye, we injected 1000X the effective dose previously used in
our light-damage model in rats [17]. Each eye received 2 ml of
1 mM nanoceria (344 ng). We harvested the eyes at different times
after injection: from 1 hour to 120 days. The Ce levels were
assessed using a 7700 Series ICP-MS from Agilent technologies
that was capable of detecting Ce at a minimum range of 50–100
parts per trillion. Figure 2 shows the retention of nanoceria in the
eye after a single intravitreal injection. This data set shows the
combined amount of nanoceria from each eye that had been
dissected into component parts: retina, lens, and rest of eye cup.
Another experiment, in which whole eyes were analyzed at 1 hour
and 30 days post injection, showed similar results (data not shown).
Surprisingly, we found that 90% of the injected nanoceria
remained in the eye after 120 days. Unlike many ophthalmic
agents such as peptides, nucleic acids or organic compounds that
are cleared from the eye within hours or days, we observed that
nanoceria were not actively eliminated from the eye. Additional
retention data from 8- and 12-month time points became available
after our submission. We determined that the elimination half-life
of nanoceria in the eye and in the retina to be 525 days and 414
days, respectively. These data are presented in Figures S1 and
S2.
PLOS ONE | www.plosone.org

Figure 3. Bio-distribution of nanoceria in ocular tissues one
hour post injection. We detected the highest concentration and
amount of nanoceria in the retinal portion of the eye whereas the lens
and the rest of the eye cup retained only small amounts of nanoceria
one hour post injection.
doi:10.1371/journal.pone.0058431.g003
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Figure 4. The retina retained nanoceria over prolonged periods of time following a single intravitreal injection. The injected nanoceria
accumulated in the retina rapidly. We detected 94% of the injected nanoceria in the retina after one hour of injection and about 70% of the injected
nanoceria was retained for the four months tested.
doi:10.1371/journal.pone.0058431.g004

remaining in the retina over the 120-day period. We observed that
about 70% of the injected nanoceria were retained in the retina
even after 120 days. (New data from 8- to 12- month samples can
be found in Figure S2.).

conclude that nanoceria generated according to our described
formulation and procedure, are not toxic to the rat retina as
measured by morphology or function, even when 344 ng are
present for over 4 months.

4. Nanoceria did not have Cytotoxic Effects in the Retina

Discussion

To assess the safety of nanoceria for therapeutic treatment, we
ascertained the effects of nanoceria in the retina after 9, 60 and
120 days post intravitreal injection. We administered a range of
nanoceria dosages (1 mM, 100 mM, and 1 mM) to the rat eyes, and
evaluated potential morphological and functional changes in the
retina. For retinal cytoarchitecture assessment, we examined the
thicknesses of the inner and outer retina (Figure 1B). The layer
thickness reflects the number of neurons residing in these two
layers, thus the overall health of the retina. We also included the
thickness of the rod inner and outer segments (IOS) to further
evaluate the health status of rod cells. We focus on the rod
photoreceptor cells because they are one of the key light sensors
and are the most abundant cell type in many mammalian retinas,
including rodents and primates [28,29]. They are also exquisitely
susceptible to oxidative damage due to the unusually high content
of polyunsaturated fatty acids [30]. Evaluation of the thickness of
IOS, therefore, can serve as an indicator of the health status of
these cells. To evaluate functional changes, we conducted scotopic,
photopic, and flicker full field ERG recordings. Scotopic a-wave
amplitude reflects primarily the function of rod cells. Scotopic bwave amplitude reflects the function of neurons in the inner retina,
post-synaptic to the rod photoreceptor cells. Photopic b-wave
amplitude and flicker ERG reflect the function of cone cells [26].
Figure 5 shows the morphometric data from 9 days post
injection. From the four surveyed areas: superior and inferior
central retina, superior and inferior peripheral retina (see
Figure 1A for orientation), we did not observe any reduction in
thickness in the layers examined for nanoceria injected eyes.
Figure S3 shows representative H&E stained retinal sections from
the inferior central portion of each eye for this set of the
experiment. We also did not observe any changes in retinal
functions among the nanoceria injected versus the saline injected
animals (Figure 6). These results indicate that nanoceria did not
cause acute negative side effects in the healthy retina. Similar
results were obtained for the 60 days (data not shown) and the 120
days (Figures 7, 8, and S4) data sets. From these results, we

This is the first in vivo study to show that nanoceria are rapidly
and preferentially taken up and retained in the retina after a single
intravitreal injection. The retention of nanoceria in the retina does
not have any short- or long-term cytotoxic effects. This study is a
more targeted approach to understanding the bio-distribution and
side-effects of nanoceria in rodent ocular tissues. The lack of toxic
effects in the retina is consistent with our previous findings
demonstrating that weekly systemic administration of nanoceria in
mice did not have cytotoxic effects in the heart, kidney, brain,
lungs, spleen, and liver for a 5-week period [31].
We do not yet know how nanoceria are taken up by retinal cells.
However, in an in vitro uptake experiment, Singh and colleagues
[32] showed that fluorescein-conjugated nanoceria were taken up
by keratinocytes via clathrin-, and caveolae-dependent endocytic
pathways. These fluorescently-labeled nanoceria were found in
multiple cellular compartments including the mitochondria,
lysosomes, endoplasmic reticulum, the nucleus, and the cytoplasm.
At this moment, kinetic studies on elimination or exocytosis of
nanoceria by cells are not available. However, in this in vivo study,
we established that the elimination half-life in the rat retina to be
414 days (see Supplemental Materials). Our results suggest that the
rate of elimination by cells is extremely slow. By 120 days, we
observed 30% reduction of injected nanoceria in the retina. Could
these nanoceria be accumulating in other organs? We detected
trace amounts of nanoceria in liver and kidney tissues from 120
days animals from both nanoceria injected and uninjected animals
(data not shown). Our findings suggest that nanoceria are removed
from the eye eventually but the primary route of elimination is
unknown. It can be by general circulation or locally in the eye, or
both. The protracted retention of nanoceria in the eye could be
beneficial if the self-regenerative property of nanoceria [33] is
maintained. Presently, we have shown that nanoceria are not toxic
to retinal neurons after 120 days of exposure and the prolonged
retention in the retina should be an asset for the investigation and
development of nanoceria as ophthalmic therapeutics.

PLOS ONE | www.plosone.org
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Figure 5. Nanoceria had no toxic effects on the morphological structures of the retina at nine days post injection. We performed
quantitative morphometric analyses (see Figure 4 legend) on the central (A–B), and peripheral (C–D) portions of the retina of animals from different
treatment groups (UI = uninjected, Sal = saline injected, or CeNP injected with the indicated dosage) and found no changes induced by nanoceria.
Representative photomicrographs of retinal sections from this time point are shown in Figure S3.
doi:10.1371/journal.pone.0058431.g005

PLOS ONE | www.plosone.org
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Figure 6. Nanoceria had no negative effects on retinal function as evaluated by ERG recordings nine days post injection. We did not
observe changes in amplitudes of scotopic a- and b-waves, photopic b-wave, and flicker at the frequencies indicated.
doi:10.1371/journal.pone.0058431.g006

interactions between nanomaterials and biological environments.
We caution that the observations made regarding interactions of
nanomaterials on synthetic membranes or lipid bilayers and
nanomaterials uptake in cell culture studies do not necessarily
reflect the actual interactions in biological environments. For
in vivo systemic delivery, the administered nanomaterials need to
circulate in the blood to reach their target tissue. En route, the
nanomaterials are likely to have serum proteins adsorbed on the
surface through electrostatic or hydrophobic interactions. This
adsorption may change the properties of how the nanomaterials
will be taken up by target cells.
In this study, we demonstrated that nanoceria administered in
the vitreous were able to penetrate through this complex structure
and reach the underlying retinal cells. The mammalian vitreous
body is a network of collagen fibers embedded in a matrix of
highly water-bound glycosaminoglycans [38]. Albumin constitutes
about 40% of the soluble proteins in the vitreous [38] and may
adsorb to the injected positively-charged nanoceria by electrostatic
interactions [39]. However, this potential interaction did not
impede the uptake of nanoceria by retinal cells. One unusual
feature of the vitreous is the high percentage of iron-binding
proteins present compared to the plasma. Van Bockxmeer and
coworkers [40] showed that about 35% of the soluble proteins in
the monkey vitreous were composed of transferrin and/or
lactoferrin. The high transferrin or transferrin-like proteins in
the vitreous may contribute to the rapid uptake of nanoceria by
retinal cells. We [41] previously showed that nanoceria with
positive surface charges can bind to transferrin and were taken up
by cells more efficiently than naked nanoceria at a number of
concentrations. Transferrin receptors are present in all cell types in
the body including retinal cells. We postulate that the rapid uptake

We are just beginning to unravel the interactions of nanoceria in
the complex biological environment. Reports of the differential
effects of nanoceria on a variety of cell types in cell culture
experiments add to the challenge of developing nanoceria for
therapeutic treatments. One major defining feature in these cell
culture studies that was seldom discussed was the synthesis and
characterization of nanoceria administered [2]. For example, the
usage of hexamethylenetetramine (HMT) in the synthesis of
nanoceria might contribute to the cytotoxic effects of nanoceria
(unpublished observations). The effects of particle aggregation
might be another contributor to the negative effects of nanoceria
observed in some cell culture studies [34,35]. The surface charge
of nanoparticles plays a major role in their uptake by cells [34].
Asati and colleagues [36] showed that polymer-coated nanoceria
with a positive charge were taken up by more cell types than the
negatively-charged or neutrally-charged particles. They also
demonstrated that the differently charged particles could be
localized in the same or different cellular compartments depending
on the cell type.
Delivery of nanoparticles to their site of action without dilution
poses another challenge. Kim and colleagues [37] compared the
movement of fluorescently-labeled human serum albumin nanoparticles with either positive or negative surface charge, in the
vitreous and retina of the rat eye. Five hours after intravitreal
administration, the authors found that the negatively-charged
nanoparticles penetrated the vitreal barrier more easily and were
found deep in the retina from the inner limiting membrane to all
the nuclear layers and plexiform layers and even in the retinal
pigment epithelium. The seemingly contradictory findings from
cell culture versus in vivo studies with respect to nanomaterial
surface charge and uptake illustrate the complexity of the
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Figure 7. Nanoceria (1–1000 uM) had no negative effects on retinal morphology, even four months after injection, as measured by
quantitative morphometric analyses. We examined the central (A–B), and peripheral (C–D) portions of the retina of animals from different
treatment groups (UI = uninjected, Sal = saline injected, or CeNP injected with the indicated dosage), and found no changes induced by nanoceria.
Measurements were performed as indicated in Figure 4.
doi:10.1371/journal.pone.0058431.g007
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Figure 8. Nanoceria (1–1000 uM) had no negative effects on retinal function, even four months after injection, as measured by ERG
recordings. No changes were detected in amplitudes of scotopic a- and b-waves, photopic b-wave, and flicker at the frequencies indicated.
doi:10.1371/journal.pone.0058431.g008

of nanoceria may be facilitated by binding to transferrin and/or
lactoferrin in the vitreous. This hypothesis is consistent with the
observation that nanoceria-mediated photoreceptor cell protection
is not focal but is found across the entire retina rather than being
confined to the injection site [17].
In spite of the many unknown interactions of nanoceria in the
vitreous and other ocular tissues, our results suggest that our stable
water-dispersed nanoceria are likely to be taken up by one or more
cell types in the retina by an active process. The enhanced redox
capacity of nanoceria does not have negative effects in healthy
retinal cells. Finally, nanoceria appear to have an extremely slow
rate of removal once inside cells.
Currently, effective and comprehensive therapies for blinding
diseases such as age-related macular degeneration, diabetic
retinopathy, and retinitis pigmentosa are still unavailable. Targeting the reduction of reactive oxygen species by nanoceria in these
diseased eyes may be one way to prolong the life and function of
retinal cells before cures become a reality. Additionally, drug
delivery to the posterior segment of the eye, such as the retina, is
most effective when administered intravitreally. This procedure,
though simple, carries the risk of complications such as infection
and retinal detachment, especially when frequent, repeated
applications are required. Taken together, nanoceria appear to
be ideal candidates as ophthalmic antioxidants because the redox
activity of nanoceria is regenerative [33] and frequent repetitive
dosing may be avoided. We predict that nanoceria may become
the ‘‘aspirin’’ of the 21st century for the therapeutic treatment of
eye diseases whose pathologic progression associates tightly with
oxidative damage.
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